Integra LifeSciences
IART
282 hedge funds and large institutions have $3.13B invested in Integra LifeSciences in 2022 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 131 increasing their positions, 73 reducing their positions, and 35 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
79% more repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 73
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
0.45% more ownership
Funds ownership: 87.92% → 88.37% (+0.45%)
1% less funds holding
Funds holding: 284 → 282 (-2)
21% less capital invested
Capital invested by funds: $3.95B → $3.13B (-$826M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.7M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$18.8M |
| 3 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$13.1M |
| 4 |
CB
Cooke & Bieler
Philadelphia,
Pennsylvania
|
+$12.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$75.6M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$38.4M |
| 3 |
Goldman Sachs
New York
|
-$25M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$10.8M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$7.72M |
IART Hedge Fund Activity: Q3 2022 in Review
282 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q3 2022, worth a combined $3.13B — down 21% from $3.95B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new IART positions and 35 closed out — a net gain of 3 holders — while 131 added to existing stakes and 73 trimmed.
The largest buyer was BlackRock, adding an estimated $22.7M. The largest seller was Wellington Management Group, cutting an estimated $75.6M.
- 282 institutional investors held Integra LifeSciences (IART) as of Q3 2022, down from 284 in Q2 2022.
- Funds reported $3.13B of Integra LifeSciences stock for Q3 2022, down 21% quarter-over-quarter.
- 38 funds opened new Integra LifeSciences positions in Q3 2022 and 35 closed out, a net change of +3 holders.
- The largest Integra LifeSciences buyer in Q3 2022 was BlackRock, an estimated $22.7M added.
- The largest Integra LifeSciences seller in Q3 2022 was Wellington Management Group, an estimated $75.6M sold.
Based on aggregated 13F filings for Q3 2022.